ROCKVILLE, Md., May 21, 2013 /PRNewswire/ -- MacroGenics, Inc. today announced that an abstract titled, "Phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in patients with advanced solid tumors expressing the HER2 oncoprotein," will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology during the Developmental Therapeutics - Immunotherapy Oral Abstract Session on Monday, June 3 at 4:15 – 4:30 PM. The presentation will describe the results of a first-in-human study of MacroGenics' next-generation anti-HER2 monoclonal antibody, margetuximab, which is being developed to treat HER2-expressing tumors.
MacroGenics has optimized the Fc region of margetuximab to increase cancer cell killing via Antibody-Dependent Cell-mediated Cytotoxicity (ADCC). Margetuximab also has shown improved control of tumor growth in human tumor xenograft models in mice as compared to that of anti-HER2 antibodies with a wild type Fc region. A development goal for margetuximab is to enable the treatment of a broader population of patients than those eligible for treatment with current HER2-targeted therapies.
MacroGenics also announced that the first patient has received study drug in a Phase 2 clinical study evaluating margetuximab in patients with metastatic breast cancer. This study is designed to evaluate the activity of margetuximab in up to 41 patients with metastatic breast cancer whose tumors express a moderate level of the oncoprotein, HER2, represented by a 2+ score by immunohistochemistry. These tumors must also lack evidence of HER2 gene amplification as determined by FISH testing. The trial is being conducted at six sites across the United States. For more information on the clinical trial, please see www.clinicaltrials.gov.
"To date, the results of our Phase 1 s
|SOURCE MacroGenics, Inc.|
Copyright©2012 PR Newswire.
All rights reserved